Label: information for the user
galantamine
Read this label carefully before starting to take this medicine, as it contains important information for you.
Reminyl contains the active ingredient “galantamine”, an anti-dementia medication. It is used in adults to treat the symptoms of mild to moderately severe Alzheimer's disease, a type of dementia that alters brain function.
Alzheimer's disease causes an increase in memory loss, confusion, and changes in behavior, making it increasingly difficult to perform routine daily activities.
It is thought that these effects are caused by a lack of “acetylcholine”, a substance responsible for transmitting messages between brain cells. Reminyl increases the amount of acetylcholine in the brain and thus treats the symptoms of the disease.
The capsules are in the form of “prolonged release”. This means that they release the medication gradually.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Reminyl. This medication should only be used for Alzheimer's disease and is not recommended for other types of memory loss or confusion.
Severe side effects
Reminyl may cause severe skin reactions, heart problems, and seizures. You should be aware of these side effects while taking Reminyl. See section4 “Be aware of severe side effects”.
Before starting treatment with Reminyl,your doctor should know if you have or have had any of the following conditions:
Your doctor will decide if Reminyl is suitable for you or if the dose needs to be changed.
Also, inform your doctor if you have recently had surgeryon the stomach, intestine, or bladder. Your doctor will decide if Reminyl is suitable for you.
Reminyl may cause weight loss.Your doctor will check your weight regularly while you are taking Reminyl.
Children and adolescents
Reminyl is not recommended for use in children or adolescents.
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
Reminyl should not be taken with medications that work in the same way. These include:
Some medications may cause side effects with a higher probability in people taking Reminyl. These include:
If you are taking any of these medications, your doctor may give you a lower dose of Reminyl.
Reminyl may affect some anesthetics. If you are undergoing general anesthesia, inform your doctor, in advance, that you are taking Reminyl.
Consult your doctor or pharmacist if you have any doubts.
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.
Do not breastfeed while taking Reminyl.
Reminyl may make you feel dizzy or drowsy, especially during the first few weeks of treatment. If Reminyl affects you, do not drive or operate tools or machinery.
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Follow exactly the administration instructions of this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
If you are taking Reminyl tablets or oral solution and your doctor has told you that he will switch you to Reminyl prolonged-release capsules, read carefully the instructions that appear in “Switching from Reminyl tablets or oral solution to Reminyl prolonged-release capsules” in this section.
How much to take
You will start treatment with Reminyl at a low dose. The usual initial dose is 8 mg, taken once a day. Your doctor will gradually increase your dose, every 4 weeks or more, until you reach the most suitable dose for you. The maximum dose is 24 mg, taken once a day.
Your doctor will explain with which dose you should start and when to increase it.
If you are unsure of what to do or find that the effect of Reminyl is too strong or weak, inform your doctor or pharmacist.
Your doctor needs to see you regularly to check that this medication is working and to discuss with you how you feel.
If you have liver or kidney problems,your doctor may give you a reduced dose of Reminyl or may decide that this medication is not suitable for you.
Switching from Reminyl tablets or oral solution to Reminyl prolonged-release capsules
If you are currently taking Reminyl tablets or oral solution, your doctor may decide to switch you to Reminyl prolonged-release capsules. If this applies to you:
DO NOT take more than one capsule in a day. While taking a daily capsule of Reminyl prolonged-release, DO NOT take Reminyl tablets or oral solution.
How to take it
Reminyl capsules should be swallowed whole and NOT chewed or crushed. Take your dose of Reminyl once a day in the morning, with water or other liquids. Try to take Reminyl with food.
Drink plenty of liquid while taking Reminyl, to stay hydrated.
If you take more Reminyl than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or
call the Toxicology Information Service, phone: 91 562 04 20 indicating the medication and the
amount ingested.Carry the packaging with the remaining capsules with you. Signs of an overdose may include:
If you forget to take Reminyl
If you forget to take a dose, leave that dose and continue treatment as usual with the next scheduled dose.Do not take a double dose to compensate for the missed doses.
If you forget to take more than one dose, consult your doctor.
If you interrupt treatment with Reminyl
Consult your doctor before interrupting treatment with Reminyl. It is essential to continue taking this medication to treat your condition.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Be aware of severe side effects
Stop taking Reminyl and consult a doctor or go to the nearest emergency service immediatelyif you notice any of the following side effects:
Skin reactions,including:
These skin reactions are rare in people taking Reminyl (they can affect up to 1 in 1,000 people).
Heart problemsincluding changes in heart rhythm (such as slow heartbeat or extra beats) or palpitations (feeling a rapid or irregular heartbeat). Heart problems can be seen as an abnormal tracing on an electrocardiogram (ECG), and may be common in people taking Reminyl (they can affect up to 1 in 10 people).
Seizures. This is rare in people taking Reminyl (they can affect up to 1 in 100 people).
You should stop taking Reminyl and seek help immediatelyif you notice any of the mentioned side effects.
Other side effects
Frequent side effects(they can affect more than 1 in 10 people):
Frequent side effects(they can affect up to 1 in 10 people):
Rare side effects(they can affect up to 1 in 100 people):
Very rare side effects(they can affect up to 1 in 1,000 people):
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet.You can also report them directly through theSpanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es/.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the label after CAD. The expiration date is the last day of the month indicated.
Do not store at a temperature above30°C.
Medicines should not be disposed of through drains or in the trash.Deposit containers and medicines that you no longer need at theSIGREpoint of the pharmacy.Ask your pharmacist how to dispose of containers and medicines that you no longer need. This way, you will help protect the environment.
Dietyl phthalate, ethylcellulose, hypromellose, macrogol 400, cornstarch, sucrose, gelatin, titanium dioxide (E171), iron oxide (E172), shellac, and propylene glycol (E1520).
Appearance of the product and contents of the package
Reminyl 8mgcapsules are white in color with the inscription “G8”. Each package contains blisters of 7 or 28 capsules or bottles of 300capsules.
Only some package sizes may be marketed.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Essential Pharma Limited,
Vision Exchange Building,
Triq it-Territorjals, Zone 1,
Central Business District,
Birkirkara, CBD 1070,
Malta
Responsible for manufacturing
Janssen-Cilag, SpA
Via C. Janssen
04100 Borgo San Michele
Latina (Italy)
This medicine is authorized in the Member States of the European Union with the following names:
BelgiumReminyl 8mg hard capsules with prolonged release
DenmarkReminyl 8mg depot capsules, hard
FinlandReminyl 8mg depot capsule, hard
GreeceReminyl 8mgcapsules with prolonged release,hard
IrelandReminyl XL 8mg prolonged release capsules
ItalyReminyl8mg rigid capsules with prolonged release
LuxembourgReminyl 8mg hard gelatin capsules with prolonged release
NorwayReminyl 8mg depot capsules, hard
SwedenReminyl 8mg depot capsules, hard
United Kingdom (Northern Ireland)Reminyl XL 8 mg prolonged release capsules
This leaflet has been approved in:October 2021.
The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/).
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.